Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

The nucleoside analog N4-hydroxycytidine (NHC) is the active metabolite of the prodrug molnupiravir, which has been approved for the treatment of COVID-19. SARS-CoV-2 incorporates NHC into its RNA, resulting in defective virus genomes. Likewise, inhibitors of dihydroorotate dehydrogenase (DHODH) red...

Descripción completa

Detalles Bibliográficos
Autores principales: Stegmann, Kim M., Dickmanns, Antje, Heinen, Natalie, Blaurock, Claudia, Karrasch, Tim, Breithaupt, Angele, Klopfleisch, Robert, Uhlig, Nadja, Eberlein, Valentina, Issmail, Leila, Herrmann, Simon T., Schreieck, Amelie, Peelen, Evelyn, Kohlhof, Hella, Sadeghi, Balal, Riek, Alexander, Speakman, John R., Groß, Uwe, Görlich, Dirk, Vitt, Daniel, Müller, Thorsten, Grunwald, Thomas, Pfaender, Stephanie, Balkema-Buschmann, Anne, Dobbelstein, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035612/
https://www.ncbi.nlm.nih.gov/pubmed/35492218
http://dx.doi.org/10.1016/j.isci.2022.104293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035612/
https://www.ncbi.nlm.nih.gov/pubmed/35492218
http://dx.doi.org/10.1016/j.isci.2022.104293

Ejemplares similares